Jamp Pharma Group, k'hamphani ea meriana ea Canada e Montréal, e phatlalalitse kajeno ho thakholoa ha Guanfacine XR, mofuta o akaretsang oa sehlahisoa sa litšupiso sa INTUNIV XR® ho tsoa Takeda Canada Inc. se sebetsanang le bothata ba ho se tsotelle (ADHD). Ho hlahisoa ha moriana ona o tloaelehileng, o fanang ka boleng bo tšoanang le o theko e tlaase, ho tla etsa hore phekolo e fihlellehe ho bakuli le ho fokotsa haholo litšenyehelo bakeng sa merero ea meriana ea sechaba le ea poraefete.
Ke sehlahisoa sa pele se phatlalalitsoeng letotong la litlhare tse ngata ho alafa bothata ba ho se tsotelle (ADHD). JAMP Pharma Group e rera ho fana ka lihlahisoa tse ngata ho finyella litlhoko tse khethehileng tsa bakuli ho latela boholo ba lithethefatsi le ponahalo. Litsenyehelo tse amanang le ADHD ho pholletsa le lilemo tsohle li hakanngoa ho feta $ 7 bilione selemo se seng le se seng Canada1, 'me JAMP Pharma Group e ikemiselitse ho hlahisa mefuta e mengata ea lihlahisoa tsena tsa niche lilemong tse tlang. Bakuli le litsebi tsa tlhokomelo ea bophelo ba ka lebella likhetho tse ngata tsa lithethefatsi tsa ADHD le ketane ea phepelo e tšepahalang, e tla matlafatsa boitlamo ba JAMP Pharma Group ho thusa ho aha bokamoso moo motho e mong le e mong a ka phelang bophelo bo phethahetseng, bo botle.
Lintlha tse ling ka sehlahisoa:
• Pontšo: Guanfacine XR (guanfacine hydrochloride extended-release tablets) e bontšoa e le monotherapy bakeng sa phekolo ea attention deficit hyperactivity disorder (ADHD) ho bana le bacha ba lilemo tse 6 ho isa ho tse 17.
• Boholo bo teng: 1 mg, 2 mg, 3 mg le 4 mg, kaofela li fumaneha ka palo ea 100.
Quotes
"Ho JAMP Pharma Group, re lula re mamela litlhoko tsa bakuli le litsebi tsa tlhokomelo ea bophelo mona Canada. Ho hlahisoa ha Guanfacine XR ho fa bana le bacha khetho e ncha ea kalafo ea ADHD. Re thabetse merero ea rona ea ho tsetela khoebong ea litlhare tse ngata tsa ADHD lilemong tse tlang le ho matlafatsa boikemelo ba meriana lekaleng lena la maemo a holimo. Seo, ha se kopantsoe le boemo ba rona ba hajoale re le moetapele oa ho qala lihlahisoa, se etsa hore JAMP Pharma Group e itšepe le ho ba le takatso e matla ho feta leha e le neng pele ho lakatsa ho ba k'hamphani e kholo ka ho fetisisa ea meriana ea Canada haufinyane.
– Bruno Mäder, Mopresidente le COO, JAMP Pharma Group
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The cost associated with ADHD across all ages is estimated to exceed $7 billion each year in Canada1, and JAMP Pharma Group intends to produce generic versions of many of these niche products in the coming years.
- JAMP Pharma Group plans to offer a wide range of products to meet the specific needs of patients in terms of drug size and appearance.
- Patients and healthcare professionals can expect more ADHD drug options and a reliable supply chain, which will strengthen JAMP Pharma Group’s commitment to help build a future where everyone can live a fuller, healthier life.
